Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Widespread use of serological tests for tuberculosis: data from 22 high-burden countries

J. Grenier, L. Pinto, D. Nair, K. Steingart, D. Dowdy, A. Ramsay, M. Pai
European Respiratory Journal 2012 39: 502-505; DOI: 10.1183/09031936.00070611
J. Grenier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Pinto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Nair
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Steingart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Dowdy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Ramsay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Pai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: madhukar.pai@mcgill.ca
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

There is great excitement over the introduction of new tuberculosis (TB) diagnostics [1]. Since 2007, several TB diagnostics and approaches have been endorsed by the World Health Organization (WHO) [2],with Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) being the most recent [3]. Amidst this excitement, there is growing concern surrounding the use of inappropriate and suboptimal TB diagnostics [4, 5].

Currently available commercial serological (antibody detection) tests for TB are inaccurate and highly inconsistent [6–8]. The International Standards for TB Care explicitly discourage their use [9]. Even so, serological tests are known to be widely used in countries such as India [2, 4, 5]. In addition to posing an economic burden on patients and healthcare systems, use of serological tests also entails potential harm to patients (e.g. unnecessary TB therapy because of false-positive results, or morbidity and mortality because of false-negative serology results).

After reviewing the evidence, including the findings of an updated meta-analysis [10], the WHO recently announced its first negative policy in TB, against the use of current TB serological tests [5, 11]. In the context of this new policy, we conducted a survey of 22 high-TB burden countries, in order to quantify the current market for serological tests and settings where they are used, and elicit perceptions about regulatory agencies.

We identified TB experts in each country and invited them to complete an electronic e-mailed survey. Although no specific selection criteria were used, we contacted a mix of public and private providers, including experts from national TB programmes. Completed surveys were obtained from at least two respondents in each of the 22 countries. When discrepant responses were noted, surveys were sent to additional experts. Thus, three or four experts were surveyed for some countries. As shown in table 1, respondents from 17 (77%) out of 22 countries reported that serological tests were on the market and being used.

View this table:
  • View inline
  • View popup
Table 1– Data from 22 high-tuberculosis (TB) burden countries on use of serological tests for the diagnosis of TB

In 13 out of the 17 countries where serological tests were used, both rapid test kits and ELISA-based assays were available, and all 17 countries had imported tests on the market. The most commonly available tests included MycoDot (Mossman Associates, Millford, MA, USA), ICT TB (ICT Diagnostics, Sydney, NSW, Australia), SD Rapid TB (SD Bio Standard Diagnostics, Gurgaon, India), Pathozyme Myco (Omega Diagnostics, Clackmannanshire, UK), TB IgG, IgM, IgA (J. Mitra & Co., Delhi, India), and Anda TB (Anda Biologicals, Strasbourg, France).

As shown in table 1, none of the 17 countries had any policies that recommended serological tests. Of these countries, 15 (88%) reported use in the private sector and eight (47%) in the public sector (all outside of the National Tuberculosis Control Programme). When asked to rank the most commonly used tests for active TB, respondents in all countries ranked microbiological techniques (sputum smears and cultures) as more frequently used than serological tests, but serological tests were generally ranked higher in the private sector than in the public sector.

Respondents from 11 (65%) out of 17 countries reported that serological tests were used as the basis for initiating therapy for active TB; those in India, Indonesia and South Africa reported that this happened “often” in the private sector. Respondents from 12 (71%) out of 17 countries perceived their regulatory agencies as being “weak”, and 11 acknowledged that such weakness may allow for the importation and/or use of serological tests. Interestingly, some respondents rated their regulatory agencies as “strong”, despite the fact that serological tests were available in these countries.

While most respondents were unable to provide much data on the volume or cost, the median cost to a patient for one test was estimated at US $12 (range $5–130). India reported the highest volume of testing, an estimated 1.5 million TB serological tests were performed, at an expenditure conservatively estimated at US $15 million per year. But serological testing was widespread in other countries as well, especially China, Indonesia, Pakistan, Vietnam and Uganda. Further work is necessary to collect more reliable estimates of test volumes and costs.

While the abuse of serological tests in India has received press coverage [4, 5, 12–15], the problem extends beyond India to most other high-burden countries. Regulation of TB diagnostics is weak in these countries, allowing for poorly performing tests to enter the market. Once on the market, financial gains by stakeholders (doctors, laboratories and diagnostic companies) keep such products profitable [4, 5, 14]. Our survey also confirms the previous observation [5, 14, 15] that companies in western countries (e.g. France, UK, USA, Germany and Australia) are exporting inaccurate and unreliable TB diagnostics to poor countries, while not approving the same tests for domestic use.

Misdiagnosis of TB is harmful both to individual patients and to public health; every missed TB diagnosis may result in additional TB transmission. Furthermore, when inaccurate and inappropriate tests are widely used, scale-up of validated diagnostics may be more difficult. While the recent WHO policy against serological TB testing provides important guidance at the global level, it will have no impact unless high-burden countries implement this policy, tighten regulations, and educate doctors, laboratories and consumers to prevent continued abuse of such diagnostics. Countries must also find ways to incentivise the private sector to substitute serological tests with validated WHO-endorsed products, such that the economic incentives of the private sector are more closely aligned with the health incentives of individual TB patients. Lastly, intensive biomarker research is urgently needed to develop accurate and reliable point-of-care serological tests that can replace the existing ineffective assays.

Acknowledgments

We are very grateful to the more than 50 TB experts who completed our surveys or provided input. We remain responsible for any errors.

Footnotes

  • Statement of Interest

    Statements of interest for K. Steingart, A. Ramsay and M. Pai can be found at www.erj.ersjournals.com/site/misc/statements.xhtml

  • ©ERS 2012

REFERENCES

  1. ↵
    1. Small PM,
    2. Pai M
    . Tuberculosis diagnosis – time for a game change. N Engl J Med 2010; 363: 1070–1071.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Pai M
    . Improving TB diagnosis: difference between knowing the path and walking the path. Expert Rev Mol Diagn 2011; 11: 241–244.
    OpenUrlPubMed
  3. ↵
    World Health Organization. Roadmap for Rolling Out Xpert MTB/RIF for Rapid Diagnosis of TB and MDR-TB. Geneva, World Health Organization, 2010.
  4. ↵
    1. Specter M
    . A Deadly Misdiagnosis. Why Millions of People Still Die from TB? New Yorker. November 15, 2010.
  5. ↵
    1. Morris K
    . WHO recommends against inaccurate tuberculosis tests. Lancet 2011; 377: 113–114.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Steingart KR,
    2. Henry M,
    3. Laal S,
    4. et al
    . A systematic review of commercial serological antibody detection tests for the diagnosis of extra-pulmonary tuberculosis. Thorax 2007; 62: 911–918.
    OpenUrlAbstract/FREE Full Text
    1. Steingart KR,
    2. Henry M,
    3. Laal S,
    4. et al
    . Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 2007; 4: e202.
    OpenUrlCrossRefPubMed
  7. ↵
    World Health Organization. Diagnostics Evaluation Series No.2. Laboratory-Based Evaluation of 19 Commercially Available Rapid Diagnostic Tests for Tuberculosis. Geneva, World Health Organization, 2008.
  8. ↵
    1. Hopewell PC,
    2. Pai M,
    3. Maher D,
    4. et al
    . International standards for tuberculosis care. Lancet Infect Dis 2006; 6: 710–725.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Steingart KR,
    2. Flores L,
    3. Dendukuri N,
    4. et al
    . Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med 2011; 8: e1001062.
    OpenUrlCrossRefPubMed
  10. ↵
    World Health Organization. Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. http://whqlibdoc.who.int/publications/2011/9789241502054_eng.pdf Date last accessed: November 4, 2011. Date last updated: 21 July 2011.
  11. ↵
    1. Mudur GS
    . India alert against TB blood tests. www.telegraphindia.com/1110721/jsp/nation/story_14268228.jsp Date last accessed: November 4, 2011. Date last updated: July 21, 2011.
    1. Mascarehnas A
    . Scientists warn against blood tests for TB, say inaccurate. www.expressindia.com/latest-news/Scientists-warn-against-blood-tests-for-TB-say-inaccurate/837274/ Date last accessed: November 4, 2011. Date last updated: August 26, 2011.
  12. ↵
    1. Pai M,
    2. Dowdy D,
    3. Steingart KR
    . Medical, public health and economic consequences of bad diagnostics for tuberculosis. http://blogs.plos.org/speakingofmedicine/2011/08/09/medical-public-health-and-economic-consequences-of-bad-diagnostics-for-tuberculosis/ Date last accessed: November 4, 2011. Date last updated: August 9, 2011.
  13. ↵
    1. Chinnock P
    . The Scandal of TB Misdiagnosis. www.tropika.net/svc/news/20101113/Chinnock-20101113-News-TB-India Date last accessed: November 4, 2011. Date last updated: November 13, 2010.
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 39 Issue 2 Table of Contents
European Respiratory Journal: 39 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Widespread use of serological tests for tuberculosis: data from 22 high-burden countries
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Widespread use of serological tests for tuberculosis: data from 22 high-burden countries
J. Grenier, L. Pinto, D. Nair, K. Steingart, D. Dowdy, A. Ramsay, M. Pai
European Respiratory Journal Feb 2012, 39 (2) 502-505; DOI: 10.1183/09031936.00070611

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Widespread use of serological tests for tuberculosis: data from 22 high-burden countries
J. Grenier, L. Pinto, D. Nair, K. Steingart, D. Dowdy, A. Ramsay, M. Pai
European Respiratory Journal Feb 2012, 39 (2) 502-505; DOI: 10.1183/09031936.00070611
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Drug concentration in lung tissue in MDR-TB
  • Obesity in COPD: the effect of water-based exercise
  • Burden of CAP in Italian general practice
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society